Five Prime Therapeutics (NASDAQ:FPRX) is set to announce its earnings results after the market closes on Wednesday, August 8th. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.08). Five Prime Therapeutics had a negative net margin of 221.74% and a negative return on equity of 44.36%. The business had revenue of $32.49 million during the quarter, compared to analysts’ expectations of $37.50 million. On average, analysts expect Five Prime Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Shares of Five Prime Therapeutics opened at $15.19 on Monday, Marketbeat reports. Five Prime Therapeutics has a 52 week low of $14.46 and a 52 week high of $48.87. The firm has a market capitalization of $534.83 million, a PE ratio of -2.82 and a beta of 3.32.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.